HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reske, S. N. Articles by Perner, S. Search for Related Content PubMed PubMed Citation Articles by Reske, S. N. Articles by Perner, S.

Imaging Prostate Cancer with ¹¹C-Choline PET/CT

¹ Department of Nuclear Medicine, University of Ulm, Ulm, Germany; ² Department of Urology, University of Ulm, Ulm, Germany; and ³ Department of Pathology, University of Ulm, Ulm, Germany

Correspondence: For correspondence or reprints contact: Sven N. Reske, MD, Department of Nuclear Medicine, University of Ulm, Robert-Koch-Straße 8, D-89081 Ulm, Germany. E-mail: sven.reske{at}uniklinik-ulm.de

The ability of ¹¹C-choline and multimodality fusion imaging with integrated PET and contrast-enhanced CT (PET/CT) was investigated to delineate prostate carcinoma (PCa) within the prostate and to differentiate cancer tissue from normal prostate, benign prostate hyperplasia, and focal chronic prostatitis. Methods: All patients with PCa gave written informed consent. Twenty-six patients with clinical stage T1, T2, or T3 and biopsy-proven PCa underwent ¹¹C-choline PET/CT after intravenous injection of 1,112 ± 131 MBq ¹¹C-choline, radical retropubic prostatovesiculectomy, and standardized prostate tissue sampling. Maximal standardized uptake values (SUVs) of ¹¹C-choline within 36 segments of the prostate were determined. PET/CT results were correlated with histopathologic results, prostate-specific antigen (PSA), Gleason score, and pT stage. Results: The SUV of ¹¹C-choline in PCa tissue was 3.5 ± 1.3 (mean ± SD) and significantly higher than that in prostate tissue with benign histopathologic lesions (2.0 ± 0.6; P < 0.001 benign histopathology vs. cancer). Visual and quantitative analyses of segmental ¹¹C-choline uptake of each patient unambiguously located PCa in 26 of 26 patients and 25 of 26 patients, respectively. A threshold SUV of 2.65 yielded an area under the receiver-operating-characteristic (ROC) curve of 0.89 ± 0.01 for correctly locating PCa. The maximal ¹¹C-choline SUV did not correlate significantly with PSA or Gleason score but did correlate with T stage (P = 0.01; Spearman r = 0.49). Conclusion: ¹¹C-Choline PET/CT can accurately detect and locate major areas with PCa and differentiate segments with PCa from those with benign hyperplasia, chronic prostatitis, or normal prostate tissue. The maximal tumoral ¹¹C-choline uptake is related to pT stage.

Key Words: prostate carcinoma • ¹¹C-choline • PET/CT

This article has been cited by other articles:

				H.-J. Wester Nuclear Imaging Probes: from Bench to Bedside Clin. Cancer Res., June 15, 2007; 13(12): 3470 - 3481. [Abstract] [Full Text] [PDF]

				J. L. Speight and M. Roach III Advances in the Treatment of Localized Prostate Cancer: The Role of Anatomic and Functional Imaging in Men Managed With Radiotherapy J. Clin. Oncol., March 10, 2007; 25(8): 987 - 995. [Abstract] [Full Text] [PDF]